Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema

Ophthalmic Surgery Lasers and Imaging

Volumn 41, Issue 1, 2010, Pages 18-25

  Li, Weiye ^a,c   Sinclair, Stephen H ^a   Xu, Guo Tong ^b,d  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PRIORITY JOURNAL; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; CHRONIC DISEASE; DIABETIC RETINOPATHY; DISEASE PROGRESSION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 76149132661     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20091230-03     Document Type: Article

References (27)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520-526.
2. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol. 1985;103:1644-1652.
3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-1806.
4. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2008;246:483-489.
5. Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des. 2007;13:2699-2712. 6. Flaharty KK, Grimm AM, Vlasses PH. Epoetin: human recombinant erythropoietin. Clin Pharm. 1989;8:769-782.
6. Ehrenreich H, Bartels C, Sargin D, Stawicki S, Krampe H. Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition. J Ren Nutr. 2008;18:146-153.
7. Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci. 2008;49:732-742.
8. Zhang JF, Wu YL, Xu JY, et al. Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits. Acta Pharmacol Sin. 2008;29:1383-1390.
9. Beck RW, Maguire MG, Bressler NM, Glassman AR, Linblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114:1804-1809.
10. Sinclair SH, Alaniz R, Presti P. Laser treatment of diabetic macular edema: comparison of ETDRS-level treatment with threshold-level treatment by using high-contrast discriminant central visual field testing. Semin Ophthalmol. 1999;14:214-222.
11. Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol. 2008;92:361-364.
12. Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130:2577-2588.
13. Zhu B, Wang W, Gu Q, Xu X. Erythropoietin protects retinal neurons and glial cells in early-stage streptozotocin-induced diabetic rats. Exp Eye Res. 2008;86:375-382.
14. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782-792.
15. Asensio-Sanchez VM, Gomez-Ramirez V, Morales-Gomez I. Erythropoietin concentrations in the vitreous body from patients with proliferative diabetic retinopathy. Arch Soc Esp Oftalmol. 2008;83:169-172.
16. Hernandez C, Fonollosa A, Garcia-Ramirez M, et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care. 2006;29:2028-2033.
17. Abu El-Asrar AM, Missotten L, Geboes K. Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol. 2007;91:822-826.
18. Katsura Y, Okano T, Matsuno K, et al. Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Care. 2005;28:2252-2254.
19. Gewirtz DA, Di X, Walker TD, Sawyer ST. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin Cancer Res. 2006;12:2232-2238.
20. Xu G-T, Zhang J, Hu L-M, Li W. Anti-VEGF effects through negative feedback regulation with intravitreal injection of erythropoietin in early diabetic retinopathy. Invest Ophthalmol Vis Sci. ARVO E-Abstract. 2009;Control/Tracking Number: 09-A-2150-ARVO.
21. Gora-Kupilas K, Josko J. The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol. 2005;43:31-39.
22. Liu XB, Wang JA, Yu SP, Keogh CL, Wei L. Therapeutic strategy of erythropoietin in neurological disorders. CNS Neurol Disord Drug Targets. 2008;7:227-234.
23. Casals-Pascual C, Idro R, Gicheru N, et al. High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria. Proc Natl Acad Sci U S A. 2008;105:2634-2639.
24. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueshi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest. 1996;74:819-825.
25. Luft FC. Erythropoietin and arterial hypertension. Clin Nephrol. 2000;53:S61-S64.
26. Kanbay M, Akcay A, Delibasi T, et al. Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure. Adv Ther. 2007;24:346-352.
27. Tovari J, Pirker R, Timar J, Ostoros G, Kovacs G, Dome B. Erythropoietin in cancer: an update. Curr Mol Med. 2008;8:481-491.